PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)

被引：34

作者：

Campbell, A.

Reckamp, K. L.

Camidge, D. R.

Giaccone, G.

Gadgeel, S. M.

Khuri, F. R.

Engelman, J. A.

Denis, L. J.

O'Connell, J. P.

Janne, P. A.

机构：

[1] Pfizer Inc, New London, CT USA

[2] City Hope Natl Med Ctr, Duarte, CA USA

[3] Univ Colorado Denver, Aurora, CO USA

[4] NCI, Bethesda, MD 20892 USA

[5] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[7] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.7596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7596

引用

页数：1